CellFE’s platform enables efficient multiplex CRISPR-Cas9 editing to engineer T cells
Managing toxicity and specificity of cell therapies relies on complex gene-editing mechanisms, requiring co-delivery of multiple gene-editing molecules.
Managing toxicity and specificity of cell therapies relies on complex gene-editing mechanisms, requiring co-delivery of multiple gene-editing molecules.
CellFE announced it has raised $3.6 million in an initial Series Seed, co-led by Cota Capital and Dynamk Capital, and joined by Embark Ventures.
CellFE will participate in one of 15 funded projects as part of $9M in funding by the National Institute for Innovation in Manufacturing Biopharmaceuticals…